HYDROCHLOROTHIAZIDE tablet

Kraj: Stany Zjednoczone

Język: angielski

Źródło: NLM (National Library of Medicine)

Składnik aktywny:

HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)

Dostępny od:

Bryant Ranch Prepack

Droga podania:

ORAL

Typ recepty:

PRESCRIPTION DRUG

Wskazania:

Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is du

Podsumowanie produktu:

Hydrochlorothiazide Tablets, USP 25 mg, are peach-colored, round, scored tablets debossed "3571" and "V" on one side. They are supplied as follows: Bottles of 30 - NDC: 63629-8991-1 Bottles of 60 - NDC: 63629-8991-2 Bottles of 90 - NDC: 63629-8991-3 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

Status autoryzacji:

Abbreviated New Drug Application

Charakterystyka produktu

HYDROCHLOROTHIAZIDE- HYDROCHLOROTHIAZIDE TABLET
BRYANT RANCH PREPACK
----------
HYDROCHLOROTHIAZIDE TABLETS, USP
25 MG AND 50 MG
RX ONLY
DESCRIPTION
Hydrochlorothiazide is a diuretic and antihypertensive. It is the
3,4-dihydro derivative of
chlorothiazide. It is chemically designated as
6-chloro-3,4-dihydro-2_H_-1,2,4-
benzothiadiazine-7-sulfonamide 1,1-dioxide and has the following
structural formula:
Hydrochlorothiazide, USP is a white, or practically white, crystalline
powder which is
slightly soluble in water, freely soluble in sodium hydroxide
solution, in _n_-butylamine, and
in dimethylformamide; sparingly soluble in methanol; insoluble in
ether, in chloroform,
and in dilute mineral acids.
Hydrochlorothiazide is supplied as 25 mg and 50 mg tablets for oral
use. Each tablet
contains the following inactive ingredients: FD&C Yellow #6 Lake,
lactose monohydrate,
magnesium stearate, microcrystalline cellulose, pregelatinized starch.
CLINICAL PHARMACOLOGY
The mechanism of the antihypertensive effect of thiazides is unknown.
Hydrochlorothiazide does not usually affect normal blood pressure.
Hydrochlorothiazide affects the distal renal tubular mechanism of
electrolyte
reabsorption. At maximal therapeutic dosage all thiazides are
approximately equal in
their diuretic efficacy.
Hydrochlorothiazide increases excretion of sodium and chloride in
approximately
equivalent amounts. Natriuresis may be accompanied by some loss of
potassium and
bicarbonate.
After oral use diuresis begins within 2 hours, peaks in about 4 hours
and lasts about 6
to 12 hours.
PHARMACOKINETICS AND METABOLISM
Hydrochlorothiazide is not metabolized but is eliminated rapidly by
the kidney. When
plasma levels have been followed for at least 24 hours, the plasma
half-life has been
observed to vary between 5.6 and 14.8 hours. At least 61% of the oral
dose is
eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the
placental but
not the blood-brain barrier and is excreted in breast milk.
INDICATIONS AND USAGE
Hydrochlorothiazide tablets are